15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
ANALYST CONSENSUS0 ratings
No Rating
Strong Buy00%
Buy00%
Hold00%
Sell00%
Strong Sell00%
Analyst rating coverage is not available for TAK yet.
12-MONTH PRICE TARGET
—
Average analyst target vs $17.54 current
Highest Target—
Average Target—
Lowest Target—
TAK EPS & revenue forecast
EPS · NEXT QUARTER
—
Range — – — · 6 analysts
Next period, 6 analysts expect Takeda Pharmaceutical Co Ltd ADR to earn — a share (range — – —), versus — a year earlier. Full-year consensus is $146.53, growing to $179.09 the year after.
REVENUE · NEXT QUARTER
$1.2T
Range $1.1T – $1.2T · 6 analysts · +4% YoY
Revenue is expected to reach $1.2T (range $1.1T – $1.2T), +4.0% year-over-year. Full-year consensus is $4.7T, rising to $4.7T next year.
TAK stock forecast FAQ
What is Takeda Pharmaceutical Co Ltd ADR's projected EPS for next quarter?+
The consensus estimate is — per share (range — – —) across 6 analysts. Full-year EPS is projected at $146.53, rising to $179.09 the following year.
How much revenue is Takeda Pharmaceutical Co Ltd ADR expected to report next quarter?+
Consensus revenue is $1.2T (range $1.1T – $1.2T). Full-year revenue is projected at $4.7T, growing to $4.7T next year.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their TAK calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
